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Abstract 
 
Background. Obesity and type 2 diabetes mellitus (T2DM) 
are two interrelated and preventable disorders. However, 
they are responsible for significant global mortality from 
cardiovascular diseases (CVDs). Clinical studies have 
demonstrated that global longitudinal strain (GLS) using 
speckle tracking echocardiography (STE), can assess 
myocardial function accurately in apparently, healthy 
patients with diabetes and obesity in the settings of acute 
and chronic ischemia and suspected cardiomyopathy 
without heart failure. No such studies have been published 
to date regarding subclinical detection of cardiac 
dysfunction among obese patients with T2DM. This 
study aims to investigate the role of STE in the early 
pre-clinical diagnosis of impairment of diastolic and 
systolic functions in obese patients with T2DM. This 
study also investigated whether it is possible to detect 
early pre-clinical impairment of diastolic and systolic 
dysfunction in obese T2DM patients, via Tissue Doppler 
Imaging (TDI), maximum rate of left ventricular 
pressure development (peak dP/dt) and GLS using STE 
for comparison. 
Subjects and Methods. After clearance from the review 
board of Dibba- Hospital, Alfujairah, UAE, all the 
available records of patients with the diagnosis of 
obesity and diabetes were examined. The study included 
214 patients presenting with obesity in conjunction  
with diabetes and 93 age-matched healthy control 
subjects. Conventional transthoracic two dimensional 
echocardiography (CE), myocardial Doppler-derived 
early diastolic (E) and atrial pre systolic (A) velocities 
and GLS by STE was performed among all the patients 
and subjects along with tissue Doppler imaging (TDI). 
This study assessed maximal rate of pressure rise during 
ventricular contraction (peak dP/dt) in diabetes induced 
dilated cardiomyopathy (DCM) with mitral valve 
incompetence. Left ventricular ejection fraction (LVEF), 
GLS and TDI were also obtained, among all the 
subjects. 
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Results. The results show that cardiac functions via 
conventional echocardiography (CE) were similar in the 
2 groups. Using TDI and conventional mitral Doppler 
flow, obese subjects with diabetes showed an evidence 
of diastolic function abnormalities in the form of  
lower mitral annular early septal (Ea) velocity (9.5 ± 2.9 
vs. 18.4 ± 3.5 cm/s, p < 0.0001), an increased  
mitral annular late (Aa) velocity (16.5 ± 2.4 vs. 14.1 ± 
2.2 cm/s, p < 0.05), higher left ventricular filling 
pressure (E/Ea = 12 ± 4.4 vs 8 ± 3.1), p < 0.05), as  
well as a reduced Ea/Aa ratio (1.00 ± 0.2 vs. 1.45 ± 0.3, 
p < 0.0001, in the study group versus control group. 
respectively. This study also showed that severely  
obese subjects (BMI >35) (n = 26) had reduced left 
ventricular (LV) systolic and diastolic functions 
compared with healthy controls. Regarding, systolic 
function indices, the findings revealed lower average 
longitudinal peak systolic strain (GLS), -13.5% ±1.4  
vs -19.54% ± 4.5; in a symptomatic patients versus  
age matched healthy subjects respectively, (p < 0.001), 
although, LVEF remained normal (56.48% ± 8.81). 
Among patients with DCM (n = 26), the findings  
reveal that global longitudinal systolic strain (GLS) is 
highly correlated with maximum rate of LV pressure 
development (dp/dt), although the LVEF remained 
normal, in comparison to GLS and dp/dt. (-9.54 ±  
4.50 and 849.9 ± 277.0); respectively, r =.790,  
*p< 0.001). However, the frequency/grade of DCM 
detected by STE, among patients having obesity  
with T2DM, correlated closely with the degree of 
obesity, metabolic abnormalities and clustering of  
other major risk factors, especially high blood pressure. 
The findings also revealed that chest pain due to 
coronary heart disease (CAD), dyspnea and DCM  
were more common among female patients compared to 
men. 
Conclusion. The results indicate that patients having 
obesity with T2DM should be advised to undertake early 
TDI and STE for early diagnosis of decreased cardiac 
diastolic and systolic functions and cardiomyopathy, 
which is likely to be missed by conventional 
echocardiography. Significant differences in regional 
and global strain were also identified between the 
severely obese diabetic (BMI ≥ 35) patients compared to 
less obese subjects. 
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It is now well established that obesity is a major 
global risk factor for type 2 diabetes mellitus (T2DM) 
which is often referred to as diabesity [1-3]. It has 
also been estimated that over 80% of all obese 
patients will develop T2DM [1]. Previously, people 
over 40 years of age were diagnosed with T2DM,  
but now children as young as 12-15 years of  
age develop T2DM because of their obesity. The 
prevalence of the 2 disorders has reached epidemic 
proportion globally especially in terms of the extent 
of their negative impact on the health of the victims 
when compared to people who smoke and have 
hypercholesterolemia [3, 4]. In addition, T2DM and 
obesity are important contributors to non-ischemic 
heart failure (HF). Diabetic cardiomyopathy (DCM), 
a term coined several years ago, refers to cardio-
myopathy in diabetic patients not attributable to  
other underlying cardiac problems, namely coronary 
artery disease (CAD), valvular disease, hypertension 
or dyslipidemia [2]. The development of DCM is 
most likely multifactorial. Putative mechanisms 
described by Xie Y and Xie Z [3] include metabolic 
disturbances, such as defective glycolysis and glucose 
oxidation, myocardial fibrosis, small vessel disease, 
autonomic dysfunction and abnormalities of calcium 
handling. It is now well established that metabolic 
cardiomyopathy can lead to several changes in  
cardiac structure and function that can be recognized 
by imaging in the asymptomatic phase, and these 
parameters can be used for monitoring either the 
progression of the disease or the response to therapy. 
This recent revelation has indicated that metabolic 
syndrome, obesity and diabetes are independent 
predictors of CAD, HF and sudden cardiac death 
(SCD). The Strong Heart Study demonstrated  
an almost 3 decades strong association between 
T2DM and higher left ventricular mass (LVM),  
wall thickness, increased arterial stiffness and  
systolic dysfunction compared with age -matched 
healthy controls [4]. It is now well established  
that both obesity and T2DM can lead to the devel-
opment cardiovascular diseases (CVDs) if left un-
treated.  
Recently, novel clinical techniques, such as 
Tissue Doppler Imaging (TDI) and global longit-
udinal strain (GLS) evaluated by speckle tracking 
echocardiography (STE) have been developed  
to detect early preclinical stage of myocardial 
dysfunction inpatients with obesity and T2DM [5]. 
Since obesity and T2DM are independent predictors 
of CAD, HF, stroke and SCD, it is of paramount 
Pre-Clinical Detection of Myocardial Dysfunction 33 
importance to ascertain if early diagnosis of the 
patients can either delay or prevent cardiac dys-
functions in these patients. Based on data reported  
in the literature, the main purpose of this study was  
to provide a guideline to clinicians with the potential 
benefits of early detection of preclinical myocardial 
abnormalities by non- invasive real time imaging 
techniques in obesity and T2DM. The study employed 
TDI and GLS using STE to detect pre-clinical 
impairment of diastolic and systolic functions in 
obese subjects with T2DM compared to cardiac 
function observed with conventional echocard-
iography (CE). Secondly, the strategy was to 
investigate whether echocardiographic parameters  
are related to metabolic abnormalities and to  




Subjects and Methods 
 
The study complied with the Declaration of 
Helsinki and was approved by the Regional 
Committees for Medical and Health Research Ethics 
in Dibba Hospital –Al-Fujairah North Eastern 
Emirates, UAE. Informed consent was given by all 
study participants. This study recruited 214 obese 
patients (body mass index (BMI ≥ 30 kgm2) with 
uncomplicated T2DM subjects (mean age = 50.2 
±12.4 years), 88 males and 126 females and 93 age-
match healthy control subjects (mean age 48.5±11.6 
years), 34 males and 59 females. All participants 
underwent both conventional echocardiography (CE) 
with GLS by STE and TDI. Measured Doppler 
parameters included isovolumic relaxation time, 
mitral E and A wave velocities, and deceleration time. 
TDI measurements included mitral annular early (Ea) 
and late (Aa′) diastolic velocities, calculated at the 
mitral annular septal velocities. To assess left atrial 
pressure (filling pressure of LV), the ratio of peak 
conventional mitral Doppler early diastolic flow 
velocity to mitral annular septal velocity (Ea) by TDI 
(E/Ea), was calculated in all patients enrolled in this 
study and healthy control subjects. In a subgroup of 
patients with DCM (n = 26) with mitral regurgitation 
(MR), maximal rate of pressure rise during ventricular 
contraction (peak dP/dt) was measured along with 
LVEF and GLS.  
All participants underwent standard transthoracic 
echocardiography including TDI and STE (iE33; 
Philips) with a 1- to 5-MHz transducer. Chamber 
dimensions including left ventricle wall thickness and 
chamber sizes at end diastole and end systole. LVEF 
was estimated by the modified Simpson rule. Left 
atrium volumes were measured using the biplane 
area-length method. Left ventricular mass (LVM) in 
gram (g) was calculated automatically by the formula: 
1.04 × [(LV end-diastole dimension + posterior wall 
thickness + inter ventricular septum thickness) 3 – 
(LV end-diastole dimension) 3] – 13.6 and indexed to 
height to the power of 2.7 (LV mass/h2.7). STE 
analysis was performed offline using (Quantification, 
Philips software). GLS was calculated as the average 
of the negative longitudinal peak systolic strains 
(GLPSS) from 17 ventricular segments obtained  
from the apical 4-, 3-, and 2-chamber views and a line 
was traced along the LV endocardium. Around this 
line, the software selected natural acoustic markers 
moving with the tissues. Automatic frame by frame 
tracking of these markers during the heart cycle 
yielded a measure of contractility along the selected 
region of interest. Global strain values were 
automatically calculated by 3D-wall motion tracking 
for the entire length of LV myocardium in 
consecutive obese T2DM patients (n = 214) and 





Descriptive data are listed as mean ± standard 
deviation (SD) for continuous variables and as a 
percentage for discrete variables. Differences among 
the groups for baseline characteristics were compared 
using ANOVA. The collected data were tabulated and 
statistically analyzed using SPSS software statistical 
package version 26. Kruskal-Wallis test (1-way 
ANOVA) was used to compare mean values of 
studied groups if there were more than 2 groups.  
To compare 2 groups, the Mann-Whitney test  
was used. Wilcoxon singed rank test was used to 
compare mean values of ejection fraction (EF%) 
before and after intervention (medial ,device or 
surgical management). Categorical variables were 
represented as numbers and percentages. The Monte 
Carlo test was used as test of significance. The  
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level of significance was adopted at p < 0.05. In 
exploratory analyses, this study used forward  
and backward selection models to investigate the 
association of metabolic risk factors as continuous 
variables (systolic BP, waist circumference, fasting 
glucose, LDL cholesterol, and log-triglyceride  
level) with strain measures among obese- T2DM 
individuals. 
Thirty one (14%) obese T2DM patients were 
studied separately and illustratively after proof  
of significant CAD or evidence of myocardial 
ischemia (>50% luminal diameter stenosis) by Rose 






The data in Table 1 show that females were  
more common and prevalent compared to males  
in both the groups among the 214 patients with 
obesity and diabetes and the 93 age-matched control 
subjects, As presented in Table 1, CAD and coronary 
risk factors including obesity, hypertension, T2DM, 
hypercholesterolemia and smoking tobacco were 
significantly (p < 0.05) more common among study 
subjects compared to controls. The results clearly 
reveal that women who have obesity, hypertension, 
diabetes and hypercholesterolemia suffered signif-
icantly (p < 0.05) more from chest pain compared  
to men. Clinical manifestations such as dyspnea  
and palpitation and drug therapy were also 
significantly (p < 0.05) more commonly administered 
in the study group compared to control group (see 
Table 1). 
Regarding diastolic function indices, the results 
also show that cardiac function with CE was similar 
in the 2 groups (patients when compared to controls). 
Using TDI, diabetic obese subjects showed an 
evidence of diastolic function abnormalities in  
the form of lower Ea velocity (9.5 ± 2.9 vs. 18.4 ±  
3.5 cm/s, p < 0.0001), an increased Aa velocity  
(16.5 ± 2.4 vs. 14.1 ± 2.2 cm/s, p < 0.05), higher  
left ventricular filling pressure in patients (E/Ea = 12 
± 4.4) versus control (8 ± 3.1), respectively, p < 0.05. 
and a reduced Ea/Aa ratio (1.00 ± 0.2) in patients vs.  
(1.45 ± 0.3, p < 0.0001), compared with age-matched 
healthy control subjects (Figure 1). 
Transthoracic echocardiography- GLS were 
obtained in obese diabetic subjects compared to the 
93 age-matched control subjects (Random blood 
sugar < 126 mg % and BMI < 25 kg/m2) (Figure 2). 
This figure illustrates that GLS is highly correlated 
with maximum rate of LV pressure development (+ve 
dP/dt) although the LVEF is remaining normal and is 
of low sensitivity in detecting early intrinsic left  
LV myocardial contractility depression in diabetes 
induced dilated cardiomyopathy in comparison to 
systolic strain and (+ve dP/dt). 
 
Table 1. General clinical characteristics and major risk 
factors for CAD in study group in comparison  
to control group 
 
Risk Factors for CAD  
Study group 
(n = 214) 
Control group 
(n = 93) 
Women, n(%) 126 (58.8) 59(63.4) 
Men, n(%) 88(41.1) 34(36.55) 
Mean age, years 50.2 ± 12.4 48.5 ± 11.6 years 
Mean body weight, 
Kg 
88.7 ± 7.3** 68.6 ± 4.3  
BMI, Kg/m2 33.5± 3.3** 23.7 ± 2.3  
Obesity, n (%) 214(100)** 10(10.7) 
Hypertension 133 (62.15%)** 12 (12.9%) 
Diabetes mellitus 214(100)**  0 
CAD 31 (14.48%)** 0 
Tobacco intake 20 (9.34 %)* 7 (7.5%) 
CAD: Coronary artery disease; BMI: Basal metabolic index. 
Data are expressed as mean ±SD;*p < 0.05 and **p < 0.01. 
 
Interestingly, obesity T2DM women had 
increased left ventricular (LV) wall thickness (15.8 ± 
2.1 mm) vs (11.1 ± 1.4 mm) in age-matched healthy 
controls, p < 0.001, the data also revealed that BMI 
correlated closely with LVM and wall thickness  
(r = 0.624, p = 0.001) (Figure 3). 
Regarding, systolic function indices, the results 
from this study showed that severely obese subjects 
(BMI >35) had reduced LV systolic and diastolic 
function compared with healthy controls. This is 
demonstrated by lower average longitudinal peak 
systolic strain, and reduced (Ea), whereas LVEF 
remained normal (56.48% ± 8.81). Differences in 
regional and global strain were identified between the 
severely obese diabetic (BMI ≥ 35), (GLPSS (-13.5% 
± 1.4)) and the age-matched healthy subjects  
(-19.54% ± 4.5; p < 0.001) (Figures 3-5). 
Pre-Clinical Detection of Myocardial Dysfunction 35 
  
(a)      (b) 
Figure 1. Tissue Doppler (left; A) shows reduced Ea (mitral annular septal velocity) in obese patient with T2DM for over 15 
years, in the absence of any 2 dimensional echocardiographic or ECG abnormalities. On the right (B) Conventional mitral 
Doppler flow shows grade III/IV diastolic dysfunction. These images are typical for all the patients employed in this study. 
 
(a)  (b)      (c)  
Figure 2. Original images showing (A) longitudinal fibers responsible for long-axis contraction lie in the sub-endocardium 
which are particularly susceptible to the effects of fibrosis, ischemia or hypertrophy in apical 4 chamber 2-dimensional 
echocardiography with tracing the endocardium yielding GLS in one projection. (B) Bulls eye technique generated from 
apical 2,3 & 4 chamber views illustrated the impaired global longitudinal peak systolic strain (GLS) of -13% in DCM 
patient. (C) Rate of LV pressure development (+ve dP/dt) = 645mmhg/s. This figure illustrated that GLS is highly correlated 
with rate of pressure development of LV (dp/dt) although the LVEF is remaining normal and is of low sensitivity in 
detecting early intrinsic myocardial depression in diabetes induced cardiomyopathy (DCM) in comparison to global systolic 
strain and dp/dt These images are typical of several similar cases. 
 
Left Ventricular Thickness 
Figure 3. Correlation between body mass index (BMI) and LV wall thickness in the study group: Good positive correlation 
was shown between increased body weight (obesity-BMI) and left ventricular thickness, r = 0.624, p = 0.001. 
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(a)     (b) 
Figure 4. Original images of the heart of a 45 years old female patient who had T2DM (for 20 years) and arterial 
hypertension (last 5 years) with a BMI of 37 . The chocardiogram done immediately after admission to CCU with acute 
onset of progressive dyspnoea. Her echocardiography showed moderate a symmetrical septal hypertrophy and dynamic 
obstruction at LVOT (Max PG = 80mmHG), The mechanism is systolic anterior motion (SAM) of mitral valve. The data 
clearly reveal the develpment of hypertensive-induced hypertrophic obstructive cardiomyopathy in obese T2DM with LVH. 
The images are typical of several similar cases. .Dibba Hospital , UAE , Galal Eldin Nagib Elkilany. 
  
(a)     (b) 
Figure 5. (a) Global longitudinal strain (GLS) Speckle tracking echocardiography (left) which can detect any early subtle 
systolic dysfunction among obese diabetic patients. (b) Three-dimensional echocardiography (right) of patient with T2DM- 
induced dilated cardiomyopathy. These images are typical on several similar cases. GEN Elkilany. 
The depressed values of global longitudinal peak 
systolic strain (GLPSS) in apparently normal contr-
acting hearts (EF≥50-55%) were highly suggestive of 
subtle LV myocardial systolic dysfunction which 
correlated significantly to the outcome in obese 
T2DM patients with LVH and impaired LV compl-
iance, (r = .790, p < 0.001) compared to controls (see 
Tables 2). 
The results presented in Table 2 showed a strong 
correlation (r = .790) and high significance of GLS  
(p < 0.001) and +ve dP/dt (<0.043) for prediction of 
outcomes in obese patients with diabetes induced 
cardiomyopathy (DCM).  
 
Table 2. Comparison of mean and standard deviation of studied variables in relation to outcome in DCM patients 
before and after therapeutic intervention versus controls, r=.790, *p< 0.001  
 
Subjects/outcome in relation to EF, GLPSS & dp/dt EF% before intervention EF% after intervention GLPSS dp/dt 
Diabetic cardiomyopathy (n = 26) not improved 42.08 ± 13.96 35.06 ±10.10 -9.54 ± 4.50 849.9 ± 277.0 
Obese diabetes (n = 214) improved  56.48 ± 8.81 61.96 ± 7.05 -19% ± 4.5  1504.9 ± 302.4 
P value 0.010* 0.270 0.001** 0.043* 
GLPSS = global longitudinal peak systolic strain, EF = ejection fraction, dp/dt = maximal rate of pressure rise during ventricular 
contraction. LVEF: Left ventricular ejection fraction measured by biplane technique 2 dimensional echocardiography, GLPSS: Global 
longitudinal systolic strain, dp/dt,: Maximum rate of LV pressure development measured from 1st and 3rd second of mitral 
incompetence slope by continuous Doppler flow. Data are presented as mean ±SD; * p < 0.01and *8p < 0.001. 
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(a)     (b) 
Figure 6. (A) Correlation between GLPSS and Three dimensional echocardiography (LVEF) among studied control with 
normal EF (r = 0.789, p < 0.05) which is indicative of strong positive significant correlation and (B) shows the correlation 
between EF % and MR +ve Dp/dt in DCM patients, r = 0.598, p = 0.001, which indicates good positive significant 
correlation). 
In addition, maximal rate of LV pressure rise 
during isovolumic contraction phase (+ve dP/dt) and 
GLPSS differed significantly in a sub group of 26 
symptomatic DCM and control subjects (peak dP/dt 
849.9 ± 277; 0 mm Hg/s) and GLPSS (-9.54% ± 4.50) 
versus (1504.9 ± 302.4 mm Hg/s and -19.54 ± 4.5%), 
respectively, p < 0.001. These values could identify a 
subgroup of DCM patients (n = 26) at risk of future 
major cardiac events (heart failure hospitalization, 
depression of LVEF < 35%, cardiac arrest in need of 
pacing, (Table 2). Alternatively, patients who have 
normal values of LVEF (56.48% ± 8.81), GLPSS  
(-19% ± 4.5) and maximum rate of LV pressure 
development (+ve dP/dt = (1504.9 ± 302.4mmHg/s), 
showed a benign course and significant improvement 
of their symptoms without any cardiac intervention. 
These techniques had 88% sensitivity and 92% 
specificity for the detection of patients who may 





The results of the present study have shown that 
cardiac function with conventional echocardiogram 
(CE) was similar in the 2 groups; (symptomatic obese 
T2DM patients compared to age-matched controls). 
However, with the help of TDI technique and GLS 
via STE, the results show that obese T2DM patients 
revealed an enlarged heart (LVH) which is correlated 
closely with BMI (Figure 3). Once DCM is devel-
oped, LVEF depression can be identified clearly by 
CE (2- and 3-dimensional echocardiography (2DE 
and 3DE)), +ve dp/dt and GLPSS (see Figure 6). 
Similar findings have been reported by Lui et al. 
[8] who found that a contrast-enhanced cardiac 
magnetic resonance imaging can detect subclinical 
myocardial dysfunction in the early stages of T2DM 
[8]. These investigators, also reported that LV 
myocardial dysfunction was associated with impaired 
micro vascular coronary perfusion. Another study, 
using similar methods (TDI and GLS via STE) in 
obese patients, found sub-clinical differences in both 
systolic and diastolic functions, regardless of the 
presence or absence of metabolic syndrome (MS), 
although MS seems to be associated with worse 
diastolic dysfunction [9]. Compared with controls, 
metabolically healthy obese patients had lower GLS 
(−18.5 ± 2.8% in obese versus −20.8 ± 2.5% in 
controls), p ANOVA < 0.001, greater dyssynchrony 
and early diastolic dysfunction, supporting the 
concept that obesity per se may have adverse cardio-
vascular effects regardless of MS or T2DM [9].  
Furthermore, a study by Petrie [10] indicated that 
systolic displacement (motion of the atrioventricular 
plane or mitral annulus) and some myocardial 
velocities can be abnormal in some patients with 
diastolic heart failure (HF) [10]. These concordant 
results in the present study have been taken as 
evidence that heart failure is preceded by “subtle” 
systolic dysfunction and that “long-axis function” 
(GLS) can be impaired in diastolic HF. The 
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implication is that the HF syndrome is related to, if 
not, caused by these regional disturbances in long-
axis function. Similar to the present study, Ringle et 
al. [11] reported a subclinical myocardial dysfunction 
in type 1 diabetes mellitus (T1DM) patients which 
can be detected by 2- and 3-dimensional STE (2D-
STE and 3D-STE), independently of any other cardio-
vascular risk factors [11]. They concluded that DCM 
progression was indicated by a mild decrease in 
longitudinal function at the follow-up, which is 
concordant with the present study [11]. Similar to  
the present study, the investigators demonstrated  
that diabetic patients had similar LVEF (60 vs 61%; 
P  =  NS) at base line, but impaired longitudinal 
function, as indicated by 2D-GLS (-18.9 ± 2 vs -
20.5 ± 2; P  =  0.0002) and 3D-GLS (-17.5 ± 2 vs -
19 ± 2; P  =  0.003). Finally, these authors concluded 
that diabetes induced cardiomyopathy (DCM) 
definitely leads to several changes in myocardial 
structure and function that are recognizable by STE 
imaging in the preclinical- asymptomatic stage and 
these parameters should be used for monitoring the 
progression of disease or the response to therapy [11]. 
Furthermore, clinical evaluation of symptomatic 
DCM patients can be supported by estimation of b-
type natriuretic peptide (BNP) levels, which is of 
great help in distinguishing between cardiac and non-
cardiac causes of acute dyspnea in the emergency 
department [12]. However, the guidelines emphasize 
that patients with high pre-test likelihood of HF may 
be referred directly for echocardiography [13]. This is 
due to the assessment that the degree of disease 
severity and progression among a symptomatic 
diabetic patients could not be assessed accurately by 
biomarkers as BNP [14]. 
Moreover, data presented in a sub-group of CAD 
patients in the present study have clearly demonstr-
ated that GLS by 2D-STE can detect the acutely 
ischemic myocardium in diabetic patients presenting 
with acute chest pain which can be differentiated from 
DCM (Figure 7) [15]. 
The main imaging approaches for DCM identific-
ation have been demonstrated by Lorenzo-Almorós et 
al. [16]. These authors showed that several methodol-
ogies can be used for the evaluation of cardiac 
dysfunction in T1DM and T2DM patients. Either 
early, middle or late responses of DCM may be 
detected as outlined by Lorenzo-Almorós et al. [16].  
 
Figure 7. Recipient observer characterstic curve (ROC) 
showing the sensitivity and specificity of 2D Speckle 
Tracking Echocardiography [2DSTE] in detection of 
acutely ischemic myocardium in patients presenting with 
acute chest pain. Sensitivity & Specificity of GLS by 2D 
Speckle Tracking Echocardiography, showed a good 
sensitivity (80%) and specificity (93%). The data are mean 
for the recruited number of patients and controls (modified 
from ESC Preventive Cardiology 2020) permission from  
r Galal El Din Nagib El-Kilany (EUD ID: 53324); 
Diagnostic value of speckle-tracking 2d-echocardiogram in 
patients with acute chest pain and high risk of coronary 
artery disease. 
Interestingly, in the present study it was observed 
that an early stage of cardiac dysfunction in either 
diabetes-induced cardiomyopathy or in metabolic 
cardiomyopathy can be quantitatively evaluated by 
LV myocardial deformation (GLS) and myocardial 
performance by dP/dt. The maximal rate of pressure 
rise during isovolumic LV ventricular contraction 
(peak +ve dP/dt) is a good index of ventricular 
performance as prescribed previously in the literature 
[17]. Peak dP/dt is sensitive to changes in contr-
actility, insensitive to changes in afterload, and only 
mildly affected by changes in preload in comparison 
to LVEF which is sensitive to changes in after  
load and preload [17]. Moreover, both experimental 
and clinical studies have demonstrated that the  
STE method can assess myocardial function 
accurately in healthy subjects, in the settings of  
acute and chronic ischemia and diabetes–induced 
cardiomyopathy. Although, Edvardsen et al, reported 
before a systolic dysfunction in HF with normal 
ejection fraction by STE [18].There is no study 
published to date, to our knowledge, showing  
STE abnormal findings among obese T2DM patients. 
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Data from the present study indicate that GLS via 
STE and peak dP/dt can be used for accurate 
diagnosis of myocardial dysfunction in obese T2DM 
patients and progression to DCM, indicating its 
beneficial clinical use in prognosis. Interestingly, the 
present study revealed that a depressed value of 
maximum rate of LV pressure development, (+ve 
dP/dt) and GLS was highly correlated with depressed 
values of LVEF (mean value 35±10%) and major 
cardiovascular events in sub group of DCM patients 
(HF, need for pacing and cardiac death) at high 
sensitivity (80%) and specificity (92%), r = .790, p < 
0.001 (see Table 2).  
Recently, Mordi et al [19] did an interesting 
review of non-invasive imaging in diabetic cardio-
myopathy. The article concluded that echocard-
iography is of crucial importance for clinical 
assessment of cardiac structure and function and 
moreover, it provides an excellent evaluation of 
subclinical LV dysfunction using systolic strain and 
diastolic function indices measurements, which is 
concordant to the present data outlined in this study. 
These investigators recommended a comprehensive 
echocardiography (CE) study with GLS and TDI 
which should certainly be considered as a key  
part in the evaluation of early DCM [19]. Finally, 
Wen et al [20] demonstrated a high sensitivity of  
area strain derived from 3D-STE (integrating 
longitudinal and circumferential deformation) in 
detecting early and subtle LV dysfunction in patients 
with risk factors of HF which is concordant to the 
present study [20]. 
In summary: It seems that both obesity and 
T2DM are major global public health problems 
currently affecting almost 2 billion people worldwide. 
Most of the patients usually die from CVDs and to a 
lesser extent kidney failure. As such, clinical efforts 
must be made to detect DCM and nephropathy as 
early as possible. If left, either undetected or 
untreated, the patients will experience a reduced 
quality of life and subsequently, may lead to early 
morbidity. Excess weight affects two-thirds of the 
U.S. adult population and increases the risk for the 
development of diabetes and subsequently CVDs and 
strokes. All patients should be screened for obesity 
and most should be screened for pre-diabetes and 
fully confirmed diabetes [1, 6]. The best treatment for 
diabetes is early identification and intervention in 
order to prevent the disorder. Prevention of T2DM 
can be accomplished through a 7% body weight loss 
through intensive lifestyle intervention changes that 
include caloric reduction via diet modification and 






In brief, it is clear that early detection of 
subclinical myocardial dysfunction in obese diabetic 
patients can be done via STE and TDI, which may be 
important for early therapeutic interventions. Early 
diagnosis at the stage of pre-heart failure may either 
prevent or reverse heart failure, thereby improving the 
prognosis. An early stage of cardiac dysfunction  
and DCM or metabolic cardiomyopathy can be 
quantitatively evaluated via myocardial deformation 
(myocardial strain imaging) by STE, peak dP/dt and 
TDI. 
In obese T2DM asymptomatic subjects either 
with or without MS, GLS by STE and TDI should be 
used as an initial screening tool for the diagnosis of 
subtle systolic and diastolic dysfunction, even in the 
presence of a normal cardiac function with CE 
(LVEF). Although extending non-invasive imaging 
by CE and GLS to all asymptomatic diabetic and 
obese people is currently not recommended for 
public, their great and valuable information on sub-
clinical detection of early stage of LV myocardial 
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